Chinese Journal of Cancer Research

, Volume 23, Issue 4, pp 317–322

Multicenter clinical study for evaluation of efficacy and safety of transdermal fentanyl matrix patch in treatment of moderate to severe cancer pain in 474 Chinese cancer patients

Authors

  • Yu-lin Zhu
    • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast OncologyPeking University School of Oncology, Beijing Cancer Hospital & Institute
  • Guo-hong Song
    • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast OncologyPeking University School of Oncology, Beijing Cancer Hospital & Institute
  • Duan-qi Liu
    • The PLA Military General Hospital of Beijing
  • Xi Zhang
    • No. 3 People’s Hospital of Chengdu
  • Kui-feng Liu
    • The First Affiliated Hospital of Guangdong Pharmaceutical University
  • Ai-hua Zang
    • Hubei Cancer Hospital
  • Ying Cheng
    • Jilin Cancer Hospital
  • Guo-chun Cao
    • Jiangsu Cancer Hospital
  • Jun Liang
    • The Affiliated Hospital of Medical College Qingdao University
  • Xue-zhen Ma
    • Qingdao Cancer Hospital
  • Xin Ding
    • Shanghai Huaihai Hospital
  • Bin Wang
    • Suzhou Municipal Hospital
  • Wei-lian Li
    • Tianjin People’s Hospital
  • Zuo-wei Hu
    • Wuhan Integrated TCM & Western Medicine Hospital
  • Gang Feng
    • Pu Ai Hospital of Wuhan City
  • Jiang-jin Huang
    • Second Affiliated HospitalZhejiang University College of Medicine
  • Xiao Zheng
    • Zhejiang Cancer Hospital
  • Shun-chang Jiao
    • The General Hospital of the People’s Liberation Army
  • Rong Wu
    • Shengjing Hospital of China Medical University
    • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast OncologyPeking University School of Oncology, Beijing Cancer Hospital & Institute
Original Article

DOI: 10.1007/s11670-011-0317-7

Cite this article as:
Zhu, Y., Song, G., Liu, D. et al. Chin. J. Cancer Res. (2011) 23: 317. doi:10.1007/s11670-011-0317-7
  • 83 Views

Abstract

Objective

Although a new matrix formulation fentanyl has been used throughout the world for cancer pain management, few data about its efficacy and clinical outcomes associated with its use in Chinese patients have been obtained. This study aimed to assess the efficacy and safety of the new system in Chinese patients with moderate to severe cancer pain.

Methods

A total of 474 patients with moderate to severe cancer pain were enrolled in this study and were treated with the new transdermal fentanyl matrix patch (TDF) up to 2 weeks. All the patients were asked to record pain intensity, side effects, quality of life (QOL), adherence and global satisfaction. The initial dose of fentanyl was 25 μg/h titrated with opioid or according to National Comprehensive Cancer Network (NCCN) guidelines. Transdermal fentanyl was changed every three days.

Results

After 2 weeks. The mean pain intensity of the 459 evaluated patients decreased significantly from 5.63±1.26 to 2.03±1.46 (P<0.0001). The total remission rate was 91.29%, of which moderate remission rate 53.16%, obvious remission rate 25.49% and complete remission rate 12.64%. The rate of adverse events was 33.75%, 18.78% of which were moderate and 3.80% were severe. The most frequent adverse events were constipation and nausea. No fatal events were observed. The quality of life was remarkably improved after the treatment (P<0.0001).

Conclusion

The new TDF is effective and safe in treating patients with moderate to severe cancer pain, and can significantly improve the quality of life.

Key words

Transdermal fentanyl matrix patch (TDF)Cancer painEfficacySafetyQuality of life

Copyright information

© Chinese Anti-Cancer Association and Springer-Verlag Berlin Heidelberg 2011